{"mainPropery":{"diseaseId":7146,"diseaseName":"Inflammatory myofibroblastic tumor","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/7146/inflammatory-myofibroblastic-tumor","synonyms":["Inflammatory fibrosarcoma"],"synonyms-with-source":[{"name":"Inflammatory fibrosarcoma"}],"identifiers":[{"identifierType":"ORPHANET","identifierId":"178342"},{"identifierType":"UMLS","identifierId":"C0334121"}]},"diseaseCategories":[{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[],"resource descriptions":[{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/pubmed?term=%22inflammatory%20myofibroblastic%20tumor%22%5BAll%20Fields%5D%20AND%20%28Review%5Bptyp%5D%20AND%20English%5Blang%5D%29&cmd=DetailsSearch' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Inflammatory myofibroblastic tumor. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='https://clinicaltrials.gov/ct2/results?term=Inflammatory+myofibroblastic+tumor&Search=Search' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Inflammatory myofibroblastic tumor. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=178342' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1539,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/ResearchTrials_ResearchProjects_Simple.php?lng=EN&LnkId=18017&Typ=Pat' target='_blank'>Orphanet</a> lists European clinical trials, research studies, and patient registries enrolling people with this condition.&nbsp;","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1542,"resourceId":2170,"resourceName":"RePORTER","descriptionText":"The <a href='http://projectreporter.nih.gov/reporter.cfm' target='_blank'>Research Portfolio Online Reporting Tool (RePORT)</a> provides access to reports, data, and analyses of research activities at the National Institutes of Health (NIH), including information on NIH expenditures and the results of NIH-supported research.  Although these projects may not conduct studies on humans, you may want to contact the investigators to learn more. To search for studies, enter the disease name in the \"Text Search\" box.  Then click \"Submit Query\".","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/DOID:0050905' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2722,"resourceId":4053,"resourceName":"Patient Registry","descriptionText":"A registry supports research by collecting of information about patients that share something in common, such as being diagnosed with Inflammatory myofibroblastic tumor. The type of data collected can vary from registry to registry and is based on the goals and purpose of that registry. Some registries collect contact information while others collect more detailed medical information. <a href=\"https://www.nih.gov/health-information/nih-clinical-research-trials-you/list-registries\" target=\"_blank\">Learn more about registries</a>.<br />\r\n<br />\r\nRegistries for&nbsp;Inflammatory myofibroblastic tumor:<br />\r\n<a href='https://www.texaschildrens.org/north-american-inflammatory-myofibroblastic-tumor-registry' target='_blank'>North American Inflammatory Myofibroblastic Tumor Registry</a><br />&nbsp;","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"}],"overviewQuestion":{"questionId":3772,"questionText":"What is an inflammatory myofibroblastic tumor?","answerText":"An <strong>inflammatory myofibroblastic tumor</strong> (IMT) is an uncommon, usually benign (non-cancerous) tumor made up of cells called myofibroblastic spindle cells. It usually develops in children or young adults, but can affect people of any age. An IMT can occur in almost any part of the body but is most commonly found in the lung, orbit (eye socket), peritoneum (lining of the abdominal cavity and internal organs), and <a href=\"http://www.merriam-webster.com/medlineplus/mesentery\" target=\"_blank\">mesentery</a>. Signs and symptoms vary depending on the site of the tumor. Some people with an IMT are asymptomatic, while others may have nonspecific respiratory symptoms, fever, or pain. IMTs may recur, and become locally invasive and/or spread (<a href=\"http://www.cancer.gov/dictionary/?CdrID=46710\" target=\"_blank\">metastasize</a>) to other parts of the body.[2667][9797][9800][9803] However, malignant (cancerous) IMTs are rare.[14651] The underlying cause of IMTs is poorly understood.[2667][9797][9800][9803] Some cases have been linked to <a href=\"https://www.genome.gov/glossary/index.cfm?id=201\" target=\"_blank\">translocations</a>  involving the <em><a href=\"http://ghr.nlm.nih.gov/gene/ALK\" target=\"_blank\">ALK</a></em> gene.[10601] Treatment involves surgical removal when possible, although there are reports of treatment with oral steroids and <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001918.htm\" target=\"_blank\">radiation therapy</a>.[2667][9797][9800][9803]","dateModified":"2016-02-08T00:00:00"},"basicQuestions":[{"questionId":9537,"questionText":"What causes inflammatory myofibroblastic tumors?","answerText":"The underlying cause of inflammatory myofibroblastic tumors (IMTs) remains unknown. While some researchers believe it is a true neoplasm, others believe that it represents an immunologic response to an infectious or noninfectious agent. Several associations have been reported between IMT and infections, including:[9802]\r\n<ul>\r\n    <li>organizing pneumonia</li>\r\n    <li><a href=\"http://emedicine.medscape.com/article/222664-overview\" target=\"_blank\">Mycobacterium avium intracellulare</a></li>\r\n    <li>Corynebacterium equi (a bacteria that affects the lungs)</li>\r\n    <li>Campylobacter jejuni (a common cause of gastroenteritis)</li>\r\n    <li>Bacillus sphaericus</li>\r\n    <li>Coxiella burnetii</li>\r\n    <li><a href=\"http://www.cdc.gov/epstein-barr/\" target=\"_blank\">Epstein-Barr virus</a></li>\r\n    <li><a href=\"http://www.cdc.gov/ecoli/\" target=\"_blank\">E. coli</a></li>\r\n    <li>occlusive phlebitis of intrahepatic veins</li>\r\n</ul>\r\nAssociations have also been reported between IMT and:[9802]\r\n<ul>\r\n    <li>previous abdominal surgery</li>\r\n    <li>trauma</li>\r\n    <li><a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003019.htm\" target=\"_blank\">ventriculoperitoneal shunt</a></li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001918.htm\" target=\"_blank\">radiation therapy</a></li>\r\n    <li>steroid usage<span style=\"font-size: 0.9em;\">[9802]</span></li>\r\n</ul>\r\n<p>An inflammatory reaction to an underlying, low-grade malignancy has also been proposed as a cause.[9803] Because there is limited information available to support or refute any of these, the mechanism behind the development of IMTs is still unclear.[9802]</p>","dateModified":"2015-10-13T12:26:00","resourceClassificationName":"Cause","references":[{"referenceId":9802,"authors":"Karnak I, et. al","articleTitle":"Inflammatory myofibroblastic tumor in children: diagnosis and treatment","bookWebsiteJournalTitle":"J Pediatr Surg","date":"June, 2001","volume":"36(6)","pages":"908-912","url":"","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9803,"authors":"Ales Tomazic, Diana Gvardijancic, Joze Maucec, and Matjaz Homan","articleTitle":"Inflammatory myofibroblastic tumor of the pancreatic head â€“ a case report of a 6 months old child and review of the literature","bookWebsiteJournalTitle":"Radiol Oncol","date":"September, 2015","volume":"49(3)","pages":"265-270","url":"http://www.ncbi.nlm.nih.gov/pubmed/?term=26401132","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":9531,"questionText":"What is the long-term outlook for people with an inflammatory myofibroblastic tumor?","answerText":"In general, inflammatory myofibroblastic tumors (IMTs) follow a benign course with a favorable outcome after they are surgically removed. In some cases, they can be invasive, recur locally, or spread (metastasize).[9799] A metastatic IMT has a poorer prognosis and can cause death.[9800] An IMT can also be indolent, with prolonged survival despite multiple recurrences. Local recurrence rates of 15% to 37%, and distant metastasis rates of up to 11%, have been reported.[9800]<br />\r\n<br />\r\nRearrangements of genetic material involving the <em><a href=\"http://ghr.nlm.nih.gov/gene/ALK\" target=\"_blank\">ALK</a></em> gene are present in the tumor in some affected people (known as being ALK-positive). Being ALK-positive may be associated with a more favorable prognosis. One study found that a higher percentage of patients with localized disease were ALK-positive (about 60%) compared to those with multicentric (having 2 or more separate growths) IMTs (about 33%). However, the associations between prognosis and ALK status need to be validated with additional, larger studies.[9800]","dateModified":"2015-10-13T09:56:00","resourceClassificationName":"Prognosis","references":[{"referenceId":9799,"authors":"Sangeeta Palaskar, Supriya Koshti, Mahesh Maralingannavar, and Anirudha Bartake","articleTitle":"Inflammatory myofibroblastic tumor","bookWebsiteJournalTitle":"Contemp Clin Dent","date":"Oct-Dec, 2011","volume":"2(4)","pages":"274-277","url":"","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9800,"authors":"Chun YS, Wang L, Nascimento AG, Moir CR, Rodeberg DA","articleTitle":"Pediatric inflammatory myofibroblastic tumor: anaplastic lymphoma kinase (ALK) expression and prognosis","bookWebsiteJournalTitle":"Pediatr Blood Cancer","date":"November, 2005","volume":"45(6)","pages":"796-801","url":"http://www.ncbi.nlm.nih.gov/pubmed/?term=15602716","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[],"gardCases":[{"caseId":53495,"abbreviatedInquiry":"I am looking for more information about this extremely rare tumor my son had 6 years ago. I have read that there are no known cases in a person his age and was just wondering more about it. Any info you have will be greatly appreciated. He was 2 years old when he was diagnosed with having an inflammatory myofibroblastic tumor on his thyroid.","caseQuestions":[{"questionId":3772,"questionText":"What is an inflammatory myofibroblastic tumor?","answerText":"An <strong>inflammatory myofibroblastic tumor</strong> (IMT) is an uncommon, usually benign (non-cancerous) tumor made up of cells called myofibroblastic spindle cells. It usually develops in children or young adults, but can affect people of any age. An IMT can occur in almost any part of the body but is most commonly found in the lung, orbit (eye socket), peritoneum (lining of the abdominal cavity and internal organs), and <a href=\"http://www.merriam-webster.com/medlineplus/mesentery\" target=\"_blank\">mesentery</a>. Signs and symptoms vary depending on the site of the tumor. Some people with an IMT are asymptomatic, while others may have nonspecific respiratory symptoms, fever, or pain. IMTs may recur, and become locally invasive and/or spread (<a href=\"http://www.cancer.gov/dictionary/?CdrID=46710\" target=\"_blank\">metastasize</a>) to other parts of the body.[2667][9797][9800][9803] However, malignant (cancerous) IMTs are rare.[14651] The underlying cause of IMTs is poorly understood.[2667][9797][9800][9803] Some cases have been linked to <a href=\"https://www.genome.gov/glossary/index.cfm?id=201\" target=\"_blank\">translocations</a>  involving the <em><a href=\"http://ghr.nlm.nih.gov/gene/ALK\" target=\"_blank\">ALK</a></em> gene.[10601] Treatment involves surgical removal when possible, although there are reports of treatment with oral steroids and <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001918.htm\" target=\"_blank\">radiation therapy</a>.[2667][9797][9800][9803]","dateModified":"2016-02-08T00:00:00","references":[{"referenceId":2667,"authors":"Coffin CM, Hornick JL, Fletcher CD","articleTitle":"Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases","bookWebsiteJournalTitle":"American Journal of Surgical Pathology","date":"April 2007","volume":"31(4)","pages":"509-520","url":"http://www.ncbi.nlm.nih.gov/pubmed/17414097","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9797,"authors":"Jindal A, Bal A, Agarwal R","articleTitle":"Inflammatory myofibroblastic tumor of the trachea in the pediatric age group: case report and systematic review of the literature","bookWebsiteJournalTitle":"Journal of Bronchology and Interventional Pulmonology","date":"January, 2015","volume":"22(1)","pages":"58-65","url":"http://www.ncbi.nlm.nih.gov/pubmed/?term=25590486","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9800,"authors":"Chun YS, Wang L, Nascimento AG, Moir CR, Rodeberg DA","articleTitle":"Pediatric inflammatory myofibroblastic tumor: anaplastic lymphoma kinase (ALK) expression and prognosis","bookWebsiteJournalTitle":"Pediatr Blood Cancer","date":"November, 2005","volume":"45(6)","pages":"796-801","url":"http://www.ncbi.nlm.nih.gov/pubmed/?term=15602716","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9803,"authors":"Ales Tomazic, Diana Gvardijancic, Joze Maucec, and Matjaz Homan","articleTitle":"Inflammatory myofibroblastic tumor of the pancreatic head â€“ a case report of a 6 months old child and review of the literature","bookWebsiteJournalTitle":"Radiol Oncol","date":"September, 2015","volume":"49(3)","pages":"265-270","url":"http://www.ncbi.nlm.nih.gov/pubmed/?term=26401132","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10601,"authors":"","articleTitle":"ALK","bookWebsiteJournalTitle":"Genetics Home Reference (GHR)","date":"March 2011","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/gene/ALK","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14651,"authors":"Salehinejad J, Pazouki M, Gerayeli MA","articleTitle":"Malignant inflammatory myofibroblastic tumor of the maxillary sinus","bookWebsiteJournalTitle":"J Oral Maxillofac Pathol","date":"May-August, 2015","volume":"17(2)","pages":"306-310","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830248/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":9537,"questionText":"What causes inflammatory myofibroblastic tumors?","answerText":"The underlying cause of inflammatory myofibroblastic tumors (IMTs) remains unknown. While some researchers believe it is a true neoplasm, others believe that it represents an immunologic response to an infectious or noninfectious agent. Several associations have been reported between IMT and infections, including:[9802]\r\n<ul>\r\n    <li>organizing pneumonia</li>\r\n    <li><a href=\"http://emedicine.medscape.com/article/222664-overview\" target=\"_blank\">Mycobacterium avium intracellulare</a></li>\r\n    <li>Corynebacterium equi (a bacteria that affects the lungs)</li>\r\n    <li>Campylobacter jejuni (a common cause of gastroenteritis)</li>\r\n    <li>Bacillus sphaericus</li>\r\n    <li>Coxiella burnetii</li>\r\n    <li><a href=\"http://www.cdc.gov/epstein-barr/\" target=\"_blank\">Epstein-Barr virus</a></li>\r\n    <li><a href=\"http://www.cdc.gov/ecoli/\" target=\"_blank\">E. coli</a></li>\r\n    <li>occlusive phlebitis of intrahepatic veins</li>\r\n</ul>\r\nAssociations have also been reported between IMT and:[9802]\r\n<ul>\r\n    <li>previous abdominal surgery</li>\r\n    <li>trauma</li>\r\n    <li><a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003019.htm\" target=\"_blank\">ventriculoperitoneal shunt</a></li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001918.htm\" target=\"_blank\">radiation therapy</a></li>\r\n    <li>steroid usage<span style=\"font-size: 0.9em;\">[9802]</span></li>\r\n</ul>\r\n<p>An inflammatory reaction to an underlying, low-grade malignancy has also been proposed as a cause.[9803] Because there is limited information available to support or refute any of these, the mechanism behind the development of IMTs is still unclear.[9802]</p>","dateModified":"2015-10-13T12:26:00","resourceClassificationName":"Cause","references":[{"referenceId":9802,"authors":"Karnak I, et. al","articleTitle":"Inflammatory myofibroblastic tumor in children: diagnosis and treatment","bookWebsiteJournalTitle":"J Pediatr Surg","date":"June, 2001","volume":"36(6)","pages":"908-912","url":"","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9803,"authors":"Ales Tomazic, Diana Gvardijancic, Joze Maucec, and Matjaz Homan","articleTitle":"Inflammatory myofibroblastic tumor of the pancreatic head â€“ a case report of a 6 months old child and review of the literature","bookWebsiteJournalTitle":"Radiol Oncol","date":"September, 2015","volume":"49(3)","pages":"265-270","url":"http://www.ncbi.nlm.nih.gov/pubmed/?term=26401132","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":9530,"questionText":"At what age are inflammatory myofibroblastic tumors usually diagnosed?","answerText":"Inflammatory myofibroblastic tumors (IMTs) are typically diagnosed in children in young adults, within the first two decades of life.[9802] However, the age at diagnosis can vary considerably. To our knowledge, the youngest person with an IMT in the medical literature was 6 months old at the time of diagnosis (with an IMT of the pancreas). IMTs have also been reported to occur in late adulthood.[9803]","dateModified":"2015-10-13T09:55:00","references":[{"referenceId":9802,"authors":"Karnak I, et. al","articleTitle":"Inflammatory myofibroblastic tumor in children: diagnosis and treatment","bookWebsiteJournalTitle":"J Pediatr Surg","date":"June, 2001","volume":"36(6)","pages":"908-912","url":"","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9803,"authors":"Ales Tomazic, Diana Gvardijancic, Joze Maucec, and Matjaz Homan","articleTitle":"Inflammatory myofibroblastic tumor of the pancreatic head â€“ a case report of a 6 months old child and review of the literature","bookWebsiteJournalTitle":"Radiol Oncol","date":"September, 2015","volume":"49(3)","pages":"265-270","url":"http://www.ncbi.nlm.nih.gov/pubmed/?term=26401132","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":9531,"questionText":"What is the long-term outlook for people with an inflammatory myofibroblastic tumor?","answerText":"In general, inflammatory myofibroblastic tumors (IMTs) follow a benign course with a favorable outcome after they are surgically removed. In some cases, they can be invasive, recur locally, or spread (metastasize).[9799] A metastatic IMT has a poorer prognosis and can cause death.[9800] An IMT can also be indolent, with prolonged survival despite multiple recurrences. Local recurrence rates of 15% to 37%, and distant metastasis rates of up to 11%, have been reported.[9800]<br />\r\n<br />\r\nRearrangements of genetic material involving the <em><a href=\"http://ghr.nlm.nih.gov/gene/ALK\" target=\"_blank\">ALK</a></em> gene are present in the tumor in some affected people (known as being ALK-positive). Being ALK-positive may be associated with a more favorable prognosis. One study found that a higher percentage of patients with localized disease were ALK-positive (about 60%) compared to those with multicentric (having 2 or more separate growths) IMTs (about 33%). However, the associations between prognosis and ALK status need to be validated with additional, larger studies.[9800]","dateModified":"2015-10-13T09:56:00","resourceClassificationName":"Prognosis","references":[{"referenceId":9799,"authors":"Sangeeta Palaskar, Supriya Koshti, Mahesh Maralingannavar, and Anirudha Bartake","articleTitle":"Inflammatory myofibroblastic tumor","bookWebsiteJournalTitle":"Contemp Clin Dent","date":"Oct-Dec, 2011","volume":"2(4)","pages":"274-277","url":"","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9800,"authors":"Chun YS, Wang L, Nascimento AG, Moir CR, Rodeberg DA","articleTitle":"Pediatric inflammatory myofibroblastic tumor: anaplastic lymphoma kinase (ALK) expression and prognosis","bookWebsiteJournalTitle":"Pediatr Blood Cancer","date":"November, 2005","volume":"45(6)","pages":"796-801","url":"http://www.ncbi.nlm.nih.gov/pubmed/?term=15602716","authors2":"","placeOfPublication":"","publisher":""}]}]},{"caseId":28235,"abbreviatedInquiry":"How can I find out more about&nbsp;the status of research on inflammatory myfibroblastic tumor?","caseQuestions":[{"questionId":3773,"questionText":"How can I learn about research involving inflammatory myofibroblastic tumor?","answerText":"In recent years, research involving inflammatory myofibroblastic tumors has focused on the search for factors that influence prognosis. One area of study is the role of the <em><a href=\"http://ghr.nlm.nih.gov/gene/ALK\" target=\"_blank\">ALK</a>&nbsp;</em><a href=\"http://www.genome.gov/glossary/index.cfm?id=70\" target=\"_blank\">gene</a> in the development of&nbsp;inflammatory myofibroblastic tumors. Approximately 50% of these tumors have a rearrangement of the <em>ALK </em>gene, which causes the gene to be more active than normal. Researchers are trying to determine how the tumors that have this rearrangement differ from those that do not have the <em>ALK </em>rearrangement.[2667]<br />\r\n<br />\r\nThe <a href=\"http://projectreporter.nih.gov/project_info_description.cfm?aid=7744684&amp;amp;icde=5970986\" target=\"_blank\">Research Portfolio Online Reporting Tool (RePORT)</a> lists one project studying the role of the <em>ALK </em>gene in the development of tumors, including inflammatory myofibroblastic tumors.&nbsp; <br />\r\n<br />\r\nVisit our section on <a href=\"https://rarediseases.info.nih.gov/gard/7146/inflammatory-myofibroblastic-tumor/resources/6\" target=\"_blank\">Research</a> for additional resources&nbsp;where you may find research studies and clinical trials.","dateModified":"2016-02-08T00:00:00","references":[{"referenceId":2667,"authors":"Coffin CM, Hornick JL, Fletcher CD","articleTitle":"Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases","bookWebsiteJournalTitle":"American Journal of Surgical Pathology","date":"April 2007","volume":"31(4)","pages":"509-520","url":"http://www.ncbi.nlm.nih.gov/pubmed/17414097","authors2":"","placeOfPublication":"","publisher":""}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[],"EncodedName":"Inflammatory_myofibroblastic_tumor"}